YM BioSciences Announces Preclinical Data Confirming Nimotuzumab
Binds to the EGF Receptor and Potentiates Radiotherapy
MISSISSAUGA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YM
BioSciences Inc. , an oncology company that identifies, develops
and commercializes differentiated products for patients worldwide,
today announced that a study presented by investigators from Kinki
University School of Medicine and Kyoto ...
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
... YM at the AACR Translational Medicine conference held in June 2008, which demonstrated that, in tumor cells expressing moderate-to-high levels of the egf
receptor, nimotuzumab has binding equivalent to the currently marketed EGFR-targeting antibodies. The AACR 2009 presentation includes data demonstrati...
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
...rade III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the egf
tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxicity reported in almost half the patients ...
Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
... to inhibition of cancer cell growth.
HuMax-EGFr is able to induce potent immune system defense activity known as
ADCC, block growth factor binding to egf
receptors, and we now established
that HuMax-EGFr inhibits EGFR activation by limiting receptor flexibility.
This new data further underlines the pote...
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
...stered orally at a dose of
350 mg on Days 1-5 of repeated 14-day cycles. The trial is designed to
enrich for patients with activating mutations in the egf
which have been associated with improved sensitivity to other EGFR
inhibitors. Based on the selection criteria, Exelixis anticipates t...
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor
Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
combination with Tarceva was more effective than either treatment
alone in the inhibition of cell proliferation and phosphorylation
of Akt in egf
and PDGF pathways. Moreover, in combination with
Tarceva, MP470 inhibited Akt phosphorylation in LNCaP prostate
cells. Finally, the MP470/Tarceva trea...
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic
Colorectal Cancer Patients Published
...cer every 9.3 minutes.
receptors normally help regulate the growth of man... cancer cells actually require
signals mediated by egf
receptors for their survival. Residing on
the surfaces of these tumor cells, egf
receptors are activated when
naturally occurring p...
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment
In a novel cancer cell laboratory model, HuMax-EGFr effectively
inhibited the growth of tumor cells that express both mutated or
receptors. This inhibition occurred through different
mechanisms of action including direct inhibition of cancer cell
growth and an immune cell-mediat...